Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19317


Purpose:

Patients with uveal melanoma metastatic to the liver will be treated with embolization of the hepatic artery every 4 weeks. GM-CSF (granulocyte-macrophage colony simulating factor) or normal saline will be injected into one of the liver arteries with an oily contrast dye, Ethiodol. This is followed by blockage of the artery with small pieces of gelatin sponge (embolization). It is hoped with this novel approach that: - tumor cells will die due to a loss of their blood supply, - local inflammatory reactions induced by GM-CSF will kill remaining tumor cells, and - a systemic immune response against tumor cells may develop.


Study summary:

Patients with uveal melanoma metastatic to the liver will be treated with embolization of the hepatic artery every 4 weeks. GM-CSF (granulocyte-macrophage colony simulating factor) or normal saline will be injected into one of the liver arteries with an oily contrast dye, Ethiodol. This is followed by blockage of the artery with small pieces of gelatin sponge (embolization).


Criteria:

Inclusion Criteria: - Metastatic uveal melanoma in the liver with histological confirmation - Ability/willingness to give informed consent - ECOG performance status of 0 or 1 - Adequate renal, liver and bone marrow function Exclusion Criteria: - Solitary liver metastasis that is amenable to surgical removal - Presence of symptomatic liver failure including ascites and hepatic encephalopathy - Presence of extra-hepatic metastases - Untreated brain metastases - Uncontrolled hypertension or congestive heart failure or acute myocardial infarction within 6 months of entry - Presence of any other medical complication that imply survival of less than six months - Uncontrolled sever bleeding tendency or active GI bleeding - Significant allergic reaction to contrast dye or GM-CSF - Immunosuppressive treatments such as systemic steroids, radiation to pelvis or systemic chemotherapy within 4 weeks - Previous embolization of the hepatic artery or intrahepatic arterial chemotherapy of liver metastasis - Active hepatitis with serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) greater than 5 x normal - HIV infection positive by ELISA - Pregnancy or breast feeding women - Biliary obstruction, biliary stent or prior biliary surgery except cholecystectomy - Significant arteriovenous shunt identified on angiography of the hepatic artery - Occlusion of main portal vein or inadequate collateral flow around an occluded portal vein


NCT ID:

NCT00661622


Primary Contact:

Principal Investigator
Takami Sato, M.D., Ph.D.
Thomas Jefferson University


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19317
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.